Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 401–500 of 1,733
Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism
Earl, J. A., & Kim, E. D. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1612239 · Cited by 20
Testosterone, Diabetes Risk, and Diabetes Prevention in Men
Yeap, B. B., & Wittert, G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.004 · Cited by 21
Rosenberg, E. A., Bůžková, P., Fink, H. A., Robbins, J. A., Shores, M. M., Matsumoto, A. M., & Mukamal, K. J. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154399 · Cited by 23
Self-citationPlatz, E. A., Barber, J. R., Chadid, S., Lu, J., Dobs, A. S., Kanarek, N., Nelson, W. G., Bradwin, G., McGlynn, K. A., & Rohrmann, S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00151 · Cited by 19
“One guideline recommends against routine testosterone therapy for older men with low testosterone and instead recommends individualized decision-making for men 65 years and older who are symptomatic and have documented low testosterone [13].”
BackgroundVena, W., Pizzocaro, A., Maida, G., Amer, M., Voza, A., Pasquale, A. D., Reggiani, F., Ciccarelli, M., Fedeli, C., Santi, D., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01700-7 · Cited by 22
“Indeed, according to reference guidelines [21], diagnosis of hypogonadism should be based on morning (08.”
Prevalence of hypogonadism in patients with type 2 diabetes mellitus among the Indian population
Anupam, B., Shivaprasad, C., Vijaya, S., Atluri, S., Aiswarya, Y., & Nikhil, K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.006 · Cited by 21
Tran, C., Yeap, B. B., Ball, J., Clayton‐Chubb, D., Hussain, S. M., Brodtmann, A. G., Tonkin, A. M., Neumann, F., Schneider, H. G., Fitzgerald, S. M., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102611 · Cited by 24
Combined Effects of Growth Hormone and Testosterone Replacement Treatment in Heart Failure
Salzano, A., Marra, A. M., Arcopinto, M., D’Assante, R., Triggiani, V., Coscioni, E., Pasquali, D., Rengo, G., Suzuki, T., Bossone, E., et al. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12520 · Cited by 20
Marcelli, M., & Mediwala, S. N. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001233 · Cited by 25
Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
Hao, X., Zhang, K., Huang, X., Yang, F., & Sun, S. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i7.636 · Cited by 20
Testosterone Disorders and Male Hypogonadism in Kidney Disease
Garibotto, G., Esposito, P. B., Picciotto, D., & Verzola, D. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.006 · Cited by 19
Mechanisms of Testosterone's Anabolic Effects on Muscle and Function: Controversies and New Insights
Bhasin, S., Wang, C., Chandra, M. R. G., Gagliano‐Jucá, T., & Jasuja, R. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf041 · Cited by 32
Self-citationThe use of hormone stimulation in male infertility
Foran, D., Chen, R., Jayasena, C. N., Minhas, S., & Tharakan, T. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102333 · Cited by 20
Cardiometabolic indices predict hypogonadism in male patients with type 2 diabetes
Caretta, N., Facondo, P., Mereu, S., Delbarba, A., Crepaldi, M., Vedovato, M., Avogaro, A., & Ferlin, A. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01941-0 · Cited by 21
“Male hypogonadism is defined as low circulating testosterone (T) level associated with signs and symptoms of testosterone deficiency, caused by organic or functional defects at multiple levels of the hypothalamic-pituitary–gonadal axis [1].”
BackgroundLaboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents
Millington, K., Lee, J. Y., Olson-Kennedy, J., Garofalo, R., Rosenthal, S. M., & Chan, Y.-M. (2024) · PEDIATRICS · doi:10.1542/peds.2023-064380 · Cited by 20
Straftis, A. A., & Gray, P. B. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183261 · Cited by 19
“Contrary to this, multiple society guidelines argue PT is indicated for men with LOH but should be considered on an individual basis, after multiple confirmations of low testosterone and the presence of hypogonadal symptoms [13,16,17,22].”
BackgroundInfluentialAccurate Measurement and Harmonized Reference Ranges for Total and Free Testosterone Levels
Jasuja, R., Pencina, K. M., Peng, L., & Bhasin, S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.002 · Cited by 22
Self-citationWang, Q., Ma, B., Fushinobu, S., Zhang, C., & Xu, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.091 · Cited by 18
Fertility outcomes in men with prior history of anabolic steroid use
Ledesma, B. R., Weber, A., Venigalla, G., Muthigi, A., Thomas, J., Narasimman, M., White, J. T., & Ramasamy, R. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.09.016 · Cited by 21
Luigi, L. D., Pigozzi, F., Sgrò, P., Frati, L., Gianfrancesco, A. D., & Cappa, M. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01145-z · Cited by 22
Kaltsas, A. (2025) · Cells · doi:10.3390/cells14120899 · Cited by 26
“With advancing age, men often experience a gradual decline in testosterone production due to a reduction in the number and function of Leydig cells [59–61].”
Gava, G., Armillotta, F., Pillastrini, P., Giagio, S., Alvisi, S., Mancini, I., Morselli, P. G., Seracchioli, R., & Meriggiola, M. C. (2021) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.12.015 · Cited by 20
de Pontual, L., & Tomé, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073477 · Cited by 21
Baliga, S., Patel, S., Naqa, I. E., Li, X. A., Cohen, L. E., Howell, R. M., Hoppe, B. S., Constine, L. S., Palmer, J. D., Hamstra, D. A., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.08.010 · Cited by 21
Klinefelter Bone Microarchitecture Evolution with Testosterone Replacement Therapy
Piot, A., Plotton, I., Boutroy, S., Bacchetta, J., Ailloud, S., Lejeune, H., Chapurlat, R. D., Szulc, P., & Confavreux, C. B. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-00956-2 · Cited by 20
“The FERTIPRESERVE project is in line with the Endocrine Society clinical practice guideline for TRT in men with hypogonadism [27] and the recent guidelines of the European Academy of Andrology (EAA) on KS [32].”
BackgroundMethodInfluentialTestosterone and Dehydroepiandrosterone Treatment in Ageing Men: Are We All Set?
Walther, A., & Seuffert, J. (2019) · The World Journal of Men s Health · doi:10.5534/wjmh.190006 · Cited by 22
“Oral formulations are easily applicable, often preferred by hypogonadal patients, but suffer from potential hepatic toxicity, while intramuscular injections on the other side are long lasting (usually applied for a period between two weeks up to three months), while dynamic dosing is difficult and assistance by a heal…”
BackgroundInfluentialCasals, G., Ferrer, R., Urgell, E., Escobar-Morreale, H. F., Argente, J., Sesmilo, G., & Biagetti, B. (2023) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2023-0020 · Cited by 32
Barocrinology: The Endocrinology of Obesity from Bench to Bedside
Kalra, S., Kapoor, N., Bhattacharya, S., Aydin, H., & Coetzee, A. (2020) · Medical Sciences · doi:10.3390/medsci8040051 · Cited by 22
“The European Society of Endocrinology (ESE) Clinical Guideline on the Endocrine Work-up in Obesity (2020) gives a detailed framework for laboratory evaluation of endocrinopathies in a patient with obesity, as outlined in Table 3 [13,16–18].”
BackgroundXia, K., Wang, F., Tan, Z., Zhang, S., Lai, X., Ou, W., Yang, C., Chen, H., Peng, H. Y., Luo, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202300993 · Cited by 23
Impact of Cushing’s syndrome on the gonadotrope axis and testicular functions in men
Papadakis, G. E., de Kalbermatten, B., Dormoy, A., Salenave, S., Trabado, S., Vieira-Pinto, O., Richa, C., Kamenický, P., Chanson, P., Maione, L., et al. (2023) · Human Reproduction · doi:10.1093/humrep/dead187 · Cited by 20
“As recommended by the Endocrine Society guidelines (Bhasin et al. , 2018), we used the cut-off of 3.0ng/ml ( ¼ 10.4nmol/l) of serum TT to define hypogonadism.”
MethodIvell, R., Heng, K., Severn, K. E., Antonio, L., Bártfai, G., Casanueva, F. F., Huhtaniemi, I. T., Giwercman, A., Maggi, M., O'Connor, D. B., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1016107 · Cited by 20
Self-citationSex steroids in serum and prostatic tissue of human cancerous prostate (STERKPROSER trial)
Meunier, M. E., Neuzillet, Y., Raynaud, J., Radulescu, C., Ghoneim, T. P., Fiet, J., Giton, F., Rouanne, M., Dreyfus, J., Lebrét, T., et al. (2018) · The Prostate · doi:10.1002/pros.23732 · Cited by 19
“, as recommended in the Endocrine Society guidelines.(15) All samples were stored immediately at −20°C.”
MethodKarl, J. P., Berryman, C. E., Harris, M. N., Lieberman, H. R., Gadde, K. M., Rood, J. C., & Pasiakos, S. M. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa024 · Cited by 17
“Those responses are consistent with hypothalamicpituitary-gonadal axis suppression [57].”
BackgroundSexual Dysfunction Among Patients With Chronic Kidney Disease
Wang, C. J., Cukor, D., & Johansen, K. L. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.10.006 · Cited by 20
Lifestyle, metabolic disorders and male hypogonadism – A one-way ticket?
Crisóstomo, L., Pereira, S., Monteiro, M. P., Raposo, J. F., Oliveira, P. F., & Alves, M. G. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110945 · Cited by 19
Advances in the treatment of functional male hypogonadism
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2296022 · Cited by 20
“…end-stage renal disease, opioids, anabolic steroid use, glucocorticoids, alcohol and marijuana abuse, systemic illness, nutritional deficiency/excessive exercise, severe obesity, some sleep disorders, organ failure (liver, heart, and lung) and comorbid illness associated with aging [6].”
BackgroundInfluentialPhelan, R., Im, A., Hunter, R. L., Inamoto, Y., Stanghellini, M. T. L., Rovó, A., Badawy, S. M., Burns, L. J., Eissa, H., Murthy, H. S., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.10.013 · Cited by 20
D’Andrea, S., Martorella, A., Castellini, C., et al. (2020) · Human Reproduction · doi:10.1093/humrep/deaa354 · Cited by 17
Maggi, M., Filippi, S., Vignozzi, L., & Rastrelli, G. (2020) · Andrology · doi:10.1111/andr.12794 · Cited by 20
Treatment of congenital hypogonadotropic hypogonadism in male patients
Lee, H. S., Shim, Y. S., & Hwang, J. S. (2022) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2244208.104 · Cited by 21
dos Santos, M. R., & Storer, T. W. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.012 · Cited by 18
Testosterone Replacement Therapy
Haymana, C., & Sönmez, A. (2022) · Management of urology · doi:10.1007/978-3-031-12049-7_20 · Cited by 19
Varanoske, A. N., Margolis, L. M., & Pasiakos, S. M. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa090 · Cited by 22
“8 nmol/L) [1] generally manifests in fat-free mass (FFM) loss and decrements in physical performance (ie, muscle strength and function) [2-5].”
BackgroundWang, A., Arver, S., Boman, K., Gerstein, H. C., Lee, S. F., Hess, S., Rydén, L., & Mellbin, L. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318819142 · Cited by 17
Pagano, M., Peruzzu, D., Busani, L., Pierdominici, M., Ruggieri, A., Antinori, A., D’Offizi, G., Petrosillo, N., Palmieri, F., Piselli, P., et al. (2021) · Biology of Sex Differences · doi:10.1186/s13293-021-00407-x · Cited by 17
“Notably, plasma testosterone levels decrease in the presence of obesity and diabetes [15], which are comorbidities frequently associated to COVID-19.”
BackgroundKohn, T. P., Agrawal, P. M., Ory, J., Hare, J. M., & Ramasamy, R. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003786 · Cited by 17
“1,2,5,7,8 While recent studies have shown that TTh-induced secondary polycythemia (Hct > 52”
BackgroundDayton, K. A., Bril, F., Barb, D., Lai, J., Kalavalapalli, S., & Cusi, K. (2021) · PLOS ONE · doi:10.1371/journal.pone.0251449 · Cited by 17
“Current Endocrine Society guidelines do not recommend routine screening of men for hypogonadism, unless associated with symptoms [29].”
BackgroundHavers, T., Held, S., Schönfelder, M., Geisler, S., & Wackerhage, H. (2025) · Sports Medicine · doi:10.1007/s40279-025-02263-w · Cited by 19
“While they can be used therapeutically e.g., in patients with hypogonadism, their use in sport is considered doping and is prohibited [46, 47].”
Zhao, H., Li, J., Li, Z., Zhang, Q., Zhong, M.-K., Yan, M., & Qiu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1182113 · Cited by 20
“TD could be caused by various conditions, including normal aging, hypogonadism, injury, or dysfunction of testicles, disorders that affect the pituitary gland and cause kidney diseases (Bhasin et al., 2018).”
BackgroundMethodInfluentialSapkota, Y., Wilson, C. L., Zaidi, A. K., Moon, W., Tacer, K. F., Lu, L., Liu, Q., Baedke, J. L., Dhaduk, R., Wang, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0093 · Cited by 17
Obstructive sleep apnea and serum total testosterone: a system review and meta-analysis
Wang, H., Lu, J., Xu, L., Yang, Y., Meng, Y., Li, Y., & Liu, B. (2022) · Sleep And Breathing · doi:10.1007/s11325-022-02655-6 · Cited by 19
Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy
Deepika, F., Ballato, E., Colleluori, G., Aguirre, L. E., Chen, R., Qualls, C., Villareal, D. T., & Armamento‐Villareal, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.915309 · Cited by 20
“The current guidelines recommendT therapy for improvement in lean mass only in men with HIV and against theuse for improvement in glycemic control inmenwith type 2 diabetes and low T (57).”
MethodEsteves, S. C., Viana, M. C., Achermann, A. P. P., & Santi, D. (2025) · Andrology · doi:10.1111/andr.70003 · Cited by 27
Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database
Cook, M. B., Beachler, D. C., Parlett, L. E., Cochetti, P. T., Finkle, W. D., Lanes, S., & Hoover, R. N. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0619 · Cited by 15
“, fatigue, reduced muscle bulk, increased body fat) that are age related (3).”
BackgroundMale hypogonadism: 14‐year prospective outcome in 550 men with type 2 diabetes
Malipatil, N. S., Yadegarfar, G., Lunt, M., Keevil, B. G., Siddals, K. W., Livingston, M. A., Roberts, S., Narayanan, R. P., Rutter, M. K., Gibson, M., et al. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.64 · Cited by 18
Endocrinopathies and cancer cachexia
Dev, R., Fabbro, E. D., & Dalal, S. (2019) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000464 · Cited by 16
“Testosterone supplementation is contraindicated in metastatic prostate or breast cancer [59]; however, there is accumulating evidence that testosterone replacement therapy may be well tolerated even after definitive treatment of prostate cancer [60].”
BackgroundRecommandations françaises de la prise en charge et du traitement de l’ostéoporose masculine
Bouvard, B., Briot, K., Legrand, É., Blain, H., Breuil, V., Chapurlat, R. D., Duquenne, M., Guggenbuhl, P., Lespessailles, É., Thomas, T., et al. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.02.024 · Cited by 24
DelConte, A., Papangkorn, K., Kim, K., Bruno, B. J., Chidambaram, N., Khera, M., Goldstein, I., Köhler, T., Miner, M. M., Dobs, A. S., et al. (2022) · Andrology · doi:10.1111/andr.13153 · Cited by 17
Oyeyemi, O. T., Oladoyin, V., Okunlola, O. A., Mosobalaje, A., Oyeyemi, I. T., Adebimpe, W. O., Nwuba, R. I., Anuoluwa, I. A., Tiamiyu, A. M., Ovuakporie-uvo, O. O., et al. (2021) · Journal of Public Health · doi:10.1007/s10389-020-01455-0 · Cited by 19
Sepu, N., Adeleye, J. O., & Kuti, M. A. (2021) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.11.014 · Cited by 16
Lood, Y., Aardal, E., Ahlner, J., Ärlemalm, A., Björn Carlsson, A., Ekman, B., Wahlberg, J., & Josefsson, M. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113823 · Cited by 18
Testosterone Replacement Therapy in the Treatment of Depression
Anderson, D. J., Vazirnia, P., Loehr, C. A., Sternfels, W., Hasoon, J. J., Viswanath, O., Kaye, A. D., & Urits, I. (2022) · Health Psychology Research · doi:10.52965/001c.38956 · Cited by 20
Testosterone replacement therapy and cardiovascular disease
Auerbach, J. M., & Khera, M. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00516-6 · Cited by 18
Erythrocytosis in Gender-Affirming Care With Testosterone
Porat, A. T., Ellwood, M., Rodina, M., & Dianat, S. (2023) · The Annals of Family Medicine · doi:10.1370/afm.3018 · Cited by 19
“15,22,23 Where hematocrit concentrations were missing but we had a hemoglobin value (14.5% of data points), we imputed the hemato-crit by multiplying the hemoglobin by a calculated factor of 3.023, which was derived as the mean multiplying factor of all the complete data.”
MethodInfluentialLim, C. A.-R., Nightingale, T. E., Elliott, S., & Krassioukov, A. V. (2019) · Spinal Cord · doi:10.1038/s41393-019-0404-z · Cited by 20
Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men
Pezzaioli, L. C., Porcelli, T., Delbarba, A., Maffezzoni, F., Focà, E., Castelli, F., Cappelli, C., Ferlin, A., & Quirós-Roldán, E. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01665-7 · Cited by 18
Adaway, J., Keevil, B. G., Miller, A. M., Monaghan, P. J., Merrett, N., & Owen, L. J. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219888549 · Cited by 17
Fallara, G., Pozzi, E., Belladelli, F., Corsini, C., Boeri, L., Capogrosso, P., Montorsi, F., & Salonia, A. (2022) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2022.05.145 · Cited by 17
JATENZO®: Challenges in the development of oral testosterone
Patel, M., Muthigi, A., & Ramasamy, R. (2021) · International Journal of Impotence Research · doi:10.1038/s41443-021-00461-4 · Cited by 18
Recommandations pratiques pour la prise en charge du déficit en testostérone
Burte, C., Lejeune, H., Faix, A., Desvaux, P., Almont, T., Cuzin, B., & Huyghe, É. (2021) · The French Journal of Urology · doi:10.1016/j.purol.2020.09.026 · Cited by 17
Clomiphene citrate improved testosterone and sperm concentration in hypogonadal males
Delu, A., Kiltz, R. J., Kuznetsov, V. A., & Trussell, J. C. (2020) · Systems Biology in Reproductive Medicine · doi:10.1080/19396368.2020.1822457 · Cited by 18
“…a TT ranging from the 2.5th percentiles of 264 ng/dL and 916 ng/dL, where 264 was recommended as the definition for hypogonadism (Travison et al. 2017); which incidentally, also defines the lower limit of normal TT according to the current Endocrine Society Guidelines (Bhasin et al. 2018).”
BackgroundInfluentialPozzi, E., Fallara, G., Belladelli, F., Corsini, C., Raffo, M., Candela, L., Schifano, N., d'Arma, A., Capogrosso, P., Boeri, L., et al. (2023) · Andrology · doi:10.1111/andr.13380 · Cited by 18
Njoroge, J. N., Tressel, W., Biggs, M. L., Matsumoto, A. M., Smith, N. L., Rosenberg, E. A., Hirsch, C. H., Gottdiener, J. S., Mukamal, K. J., & Kizer, J. R. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026953 · Cited by 20
“9 Our findings reinforce the value of this approach for older men, supporting free testosterone as the key measure for determination of HF risk.”
InfluentialSelf-citationKhera, M., Miner, M. M., Jaffe, J. S., & Pastuszak, A. W. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.10.019 · Cited by 17
Seasonal Variation of Testosterone Levels in a Large Cohort of Men
Zornitzki, T., Tshori, S., Shefer, G., Mingelgrin, S., Levy, C., & Knobler, H. (2022) · International Journal of Endocrinology · doi:10.1155/2022/6093092 · Cited by 20
“(erefore, clinical practice guidelines recommend measuring testosterone levels in the early morning hours [8].”
BackgroundCOVID-19 pandemic: what about the gonads?
Selek, A., Güçlü, M., & Bolu, Ş. E. (2021) · HORMONES · doi:10.1007/s42000-021-00277-3 · Cited by 18
Casale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 21
Corona, G., Rastrelli, G., Dicuio, M., Concetti, S., Minnetti, M., Pivonello, R., Isidori, A. M., Sforza, A., & Maggi, M. (2021) · Minerva Endocrinology · doi:10.23736/s2724-6507.20.03208-3 · Cited by 19
Electronic health record data quality variability across a multistate clinical research network
Mohamed, Y., Song, X., McMahon, T. M., Sahil, S., Zozus, M. N., Wang, Z., Collaborative, G. P., & Waitman, L. R. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.548 · Cited by 23
“This could be due to the controversies between the different scientific societies and their guidelines [24,25].”
BackgroundGender-affirming hormone therapy in the transgender patient: influence on thrombotic risk
King, H., Kelley, T. P., & Shatzel, J. J. (2024) · Hematology · doi:10.1182/hematology.2024000592 · Cited by 19
Kim, M., Byun, S., & Hong, S. K. (2020) · The World Journal of Men s Health · doi:10.5534/wjmh.190158 · Cited by 17
Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?
Bond, P., Verdegaal, T. J., & Smit, D. L. (2024) · Endocrine Connections · doi:10.1530/ec-24-0283 · Cited by 21
Testosterone Deficiency in Sickle Cell Disease: Recognition and Remediation
Musicki, B., & Burnett, A. L. “. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892184 · Cited by 20
Hormonal Replacement Therapy in Heart Failure
Salzano, A., D’Assante, R., Lander, M., Arcopinto, M., Bossone, E., Suzuki, T., & Cittadini, A. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.02.007 · Cited by 15
Update on acquired hypogonadism in men living with HIV: pathogenesis, clinic, and treatment
Vincentis, S. D., & Rochira, V. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1201696 · Cited by 19
“Second-line evaluations include pituitary function tests (especially serum prolactin) in case of confirmed secondary (hypogonadotropic) hypogonadism and magnetic resonance imaging of the pituitary if a hypothalamic-pituitary disease is suspected on the basis of severe T deficiency or concomitant other clinical feature…”
BackgroundMethodInfluentialQin, Z., Liu, N., Liao, R., Jiang, L., & Su, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.722941 · Cited by 18
“Finally, testosterone levels exhibit a circadian variation with peak levels in the morning and evidence-based guidelines recommend measuring morning TT level (64).”
BackgroundMaheshwari, A., Nippoldt, T. B., & Davidge-Pitts, C. J. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab068 · Cited by 21
“SHBG elevation can be caused by aging, various medications (estrogen, anticonvulsants, and metformin), medical conditions (liver disease, hyperthyroidism, and HIV disease) [11].”
BackgroundLeisegang, K., Finelli, R., Sikka, S. C., & Selvam, M. K. P. (2022) · Medicina · doi:10.3390/medicina58081047 · Cited by 28
Testosterone replacement therapy and spermatogenesis in reproductive age men
Naelitz, B. D., Momtazi-Mar, L., Vallabhaneni, S., Cannarella, R., Vij, S. C., Parekh, N. V., Bole, R., & Lundy, S. D. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01032-8 · Cited by 27
“Secondary testosterone deficiency results from hypothalamic or pituitary-gland dysfunction and is characterized by low androgen levels in the setting of inappropriately low or normal gonadotropin levels 49 .”
Exogenous Opioids and the Human Endocrine System: An Endocrine Society Scientific Statement
Karavitaki, N., Bettinger, J. J., Biermasz, N., Christ-Crain, M., Gadelha, M. R., Inder, W. J., Tsourdi, E., Wakeman, S. E., & Zatelli, M. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae023 · Cited by 14
Testosterone replacement therapy is associated with an increased risk of urolithiasis
McClintock, T. R., Valovska, M.-T. I., Kwon, N. K., Cole, A. P., Jiang, W., Kathrins, M. N., Bhojani, N., Haleblian, G. E., Koehlmoos, T. P., Haider, A. H., et al. (2019) · World Journal of Urology · doi:10.1007/s00345-019-02726-6 · Cited by 21
“Male hypogonadism is a syndromic diagnosis characterized by low serum testosterone levels and at least one associated clinical sign or symptom of testosterone deficiency [1].”
BackgroundPhelan, R., Im, A., Hunter, R. L., Inamoto, Y., Stanghellini, M. T. L., Rovó, A., Badawy, S. M., Burns, L. J., Eissa, H., Murthy, H. S., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01591-z · Cited by 16
Pelusi, C., Fanelli, F., Baccini, M., Triggiani, V., Bartolomeo, N., Carbone, M. D., Pergola, G. D., Dalmazi, G. D., Pagotto, U., Pasquali, R., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14122 · Cited by 19
Pharmacological management of testosterone deficiency in men current advances and future directions
Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2366505 · Cited by 19
“This view was substantially accepted by the Endocrine Society of the U.S.A. [5] and of Australia [6], but not by all [7].”
InfluentialLate‐onset hypogonadism: Prostate safety
Miranda, E., & Torres, L. O. (2020) · Andrology · doi:10.1111/andr.12772 · Cited by 18
Men's health in the modern era of cystic fibrosis
Khan, F. N., Tangpricha, V., Hughan, K. S., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.12.013 · Cited by 15
Ballato, E., Deepika, F., Russo, V., Fleires-Gutierrez, A. L., Colleluori, G., Fuenmayor, V., Chen, R., Villareal, D. T., Qualls, C., & Armamento‐Villareal, R. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-00993-x · Cited by 17
“Based on the current Endocrine Society definition [47] of”
BackgroundBuskbjerg, C. R., Zachariae, R. H., Agerbæk, M., Gravholt, C. H., Haldbo‐Classen, L., Hosseini, S. M. H., & Amidi, A. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-021-00492-x · Cited by 16
Low Testosterone in Male Cancer Patients and Survivors
Xu, P. J., Choi, E. J., White, K. M., & Yafi, F. A. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.03.004 · Cited by 16
Effects of Varicocele Repair on Testicular Endocrine Function: A Systematic Review and Meta-Analysis
Cannarella, R., Shah, R. S., Ko, E., Kavoussi, P. K., Rambhatla, A., Hamoda, T. A.-A. A.-M., Saleh, R. A., Harraz, . M., Calogero, A. E., Durairajanayagam, D., et al. (2024) · The World Journal of Men s Health · doi:10.5534/wjmh.240109 · Cited by 28
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.